reports
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 9 shares at 1,280.560USD and the significance rating of the trade was 34/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Stephane Foucaud
AUCTUS ON FRIDAY - 21/03/2025
AUCTUS PUBLICATIONS ________________________________________ Chariot (CHAR LN)C; Target price of £0.10 per share: Significant power transaction highlights the value of the S. Africa electricity trading business – Etana Energy, the South African electricity trading business (49% held by Chariot) has arranged a US$55 mm guarantee finance facility through Standard Bank and secured an equity investment of up to US$20 mm from Norfund for working capital. In exchange, Standard Bank and Norfund will ho...
EGY VAALCO ENERGY INC.
TXP TOUCHSTONE EXPLORATION
GENL GENEL ENERGY
ENI ENI S.P.A.
ALVOF ALVOPETRO ENERGY LTD
PCL PANCONTINENTAL OIL & GAS N.L.
SEI. SINTANA ENERGY
CHAR CHARIOT OIL & GAS
7777 3-D MATRIX
GKP GULF KEYSTONE PETROLEUM LTD.
DGOC DIVERSIFIED GAS & OIL
ENOG ENERGEAN PLC
BLOE BLOCK ENERGY
AOI AFRICA OIL CORP
SENX SERINUS ENERGY
JSE JADESTONE ENERGY
TAL PETROTAL (TAL)
SOUC SOUTHERN ENERGY CORP
CEQ CRITERIUM ENERGY LTD.
PRD PREDATOR OIL & GAS HOLDINGS PLC
CDR CONDOR ENERGIES INC
Moody's Ratings affirms Continental's Baa3 ratings; stable outlook
Moody's Ratings (Moody's) affirmed Baa3 senior unsecured ratings of Continental Resources, Inc.'s (Continental). The outlook on the ratings remains stable. "Continental's Baa3 rating recognizes the company's strong operating performance, consistent free cash flow generation and significan...
Moody's announces completion of a periodic review of ratings of Contin...
Moody's Ratings has completed a periodic review of the ratings of Continental Resources, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 March 2024 in which Moody's reassessed the appropriateness of the ratings in the conte...
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Martin Fan
- Andreas Argyrides
- Caroline Pocher
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Ritika Das
- Robert Driscoll
- Sam Ravina
BLUE BLUEBIRD BIO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
KO COCA-COLA COMPANY
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
ISEE IVERIC BIO
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
BCEL ATRECA
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
KDNY CHINOOK THERAPEUTICS
PASG INC.
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
FRLN ADICET BIO INC
ITOS FREELINE THERAPEUTICS HOLDINGS ADS
INZY ITEOS THERAPEUTICS
ZNTL INOZYME PHARMA
BEAM ZENTALIS PHARMACEUTICALS
GBIO BEAM THERAPEUTICS
PRAX GENERATION BIO
COGT PRAXIS PRECISION MEDICINES
TVTX COGENT BIOSCIENCES INC
KNTE TRAVERE THERAPEUTICS INC
VRDN KINNATE BIOPHARMA
VOR VIRIDIAN THERAPEUTICS INC
NUVB VOR BIOPHARMA
DAWN NUVATION BIO INC (A)
CYT DAY ONE BIOPHARMACEUTICALS INC
ELEV CYTEIR THERAPEUTICS
FHTX INC
OMGA ELEVATION ONCOLOGY
SBTX FOGHORN THERAPEUTICS
TNGX OMEGA THERAPEUTICS
LBPH SILVERBACK THERAPEUTICS
THRX TANGO THERAPEUTICS
VERA INC
TSVT LONGBOARD PHARMACEUTICALS
DSGN THESEUS PHARMACEUTICALS
ATXS INC.
AVTE VERA THERAPEUTICS INC
CMPX 2SEVENTY BIO INC
GMTX DESIGN THERAPEUTICS INC
RLYB ASTRIA THERAPEUTICS INC
JANX AEROVATE THERAPEUTICS INC
KRTX COMPASS THERAPEUTICS
FUSN GEMINI THERAPEUTICS INC
VIGL RALLYBIO CORP
MLTX JANUX THERAPEUTICS INC
RANI KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
NUVL VIGIL NEUROSCIENCE INC
OCS MOONLAKE IMMUNOTHERAPEUTICS
RANI ZIM SHOPPING CENTERS LTD
EDGEWISE THERAPEUTICS INC
NUVALENT INC
OCULIS HOLDING AG
- Wedbush Research
- David Nierengarten
- Dennis Pak
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreeme...
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.